سعر ايبرانس 100 مجم 21 كبسولة 2025

Ibrance 100 mg (Pfizer): palbociclib, an oral cyclin-dependent kinase 4/6 inhibitor used in hormone receptor-positive advanced or metastatic breast cancer; hard capsules, pack of 21.

• HR-positive, HER2-negative advanced or metastatic breast cancer in adults, with an aromatase inhibitor as initial endocrine-based therapy or with fulvestrant after progression on endocrine therapyPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer, with inavolisib and fulvestrantPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Maintenance treatment of HR-positive, HER2-positive locally advanced or metastatic breast cancer after induction, with trastuzumab (with or without pertuzumab) and endocrine therapyPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (10% or more): neutropenia, infections, leukopenia, fatigue, nausea, alopecia, stomatitis, diarrhoea, anaemia, rash, asthenia, thrombocytopenia, vomiting, decreased appetite, dry skin, pyrexia and dysgeusia. Postmarketing: interstitial lung disease/non-infectious pneumonitis and palmar-plantar erythrodysesthesia.International label, same product · DailyMed (U.S. National Library of Medicine)

• None stated in the US label.International label, same product · DailyMed (U.S. National Library of Medicine)

• Neutropenia is the most frequent adverse reaction (about 80%; Grade 3 or higher in about 66% in PALOMA-2/3); febrile neutropenia and one death from neutropenic sepsis reported. Interrupt, reduce or delay for Grade 3-4 neutropenia.International label, same product · DailyMed (U.S. National Library of Medicine)
• Severe, life-threatening or fatal interstitial lung disease/pneumonitis can occur with CDK4/6 inhibitors; monitor for pulmonary symptoms, interrupt if suspected and permanently discontinue for severe ILD/pneumonitis.International label, same product · DailyMed (U.S. National Library of Medicine)
• Embryo-fetal toxicity: pregnancy test before starting in females of reproductive potential; effective contraception during treatment and for at least 3 weeks after the last dose (females) and for 3 months after the last dose (males with female partners of reproductive potential).International label, same product · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A inhibitors (e.g. clarithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, ritonavir-containing regimens) and grapefruitItraconazole increased palbociclib exposure by 87%; avoid, or reduce palbociclib to 75 mg once daily if unavoidable.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A inducers (e.g. rifampin, phenytoin, carbamazepine, enzalutamide, St John's wort)Rifampin decreased palbociclib exposure by 85%; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
• Sensitive CYP3A substrates with a narrow therapeutic index (e.g. alfentanil, cyclosporine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus, tacrolimus)Palbociclib is a weak time-dependent CYP3A inhibitor (midazolam exposure +61%); the substrate dose may need reduction.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm based on animal findings and mechanism of action; no data in pregnant women; embryo-fetal toxicity in rats and rabbits at exposures of 4 or more times the human exposure.International label, same product · DailyMed (U.S. National Library of Medicine)
• Do not breastfeed during treatment and for 3 weeks after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)

• Palbociclib: Reversible, selective inhibitor of CDK4 and CDK6 that blocks retinoblastoma protein phosphorylation and G1-to-S cell-cycle progression.